AU2018295118B2 - Multi-specific antibodies and methods of making and using thereof - Google Patents

Multi-specific antibodies and methods of making and using thereof Download PDF

Info

Publication number
AU2018295118B2
AU2018295118B2 AU2018295118A AU2018295118A AU2018295118B2 AU 2018295118 B2 AU2018295118 B2 AU 2018295118B2 AU 2018295118 A AU2018295118 A AU 2018295118A AU 2018295118 A AU2018295118 A AU 2018295118A AU 2018295118 B2 AU2018295118 B2 AU 2018295118B2
Authority
AU
Australia
Prior art keywords
ser
gly
thr
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018295118A
Other languages
English (en)
Other versions
AU2018295118A1 (en
Inventor
Bill Brady
Katrina BYKOVA
Zeren Gao
David JELLYMAN
Brian Kovacevich
Yu Liang
Ole Olsen
Blair RENSHAW
Anne-Marie Rousseau
Dong Xia
Yi Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Systimmune Inc
Original Assignee
Systimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc filed Critical Systimmune Inc
Publication of AU2018295118A1 publication Critical patent/AU2018295118A1/en
Assigned to SYSTIMMUNE, INC., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. reassignment SYSTIMMUNE, INC. Request for Assignment Assignors: SICHUAN BAILI PHARMACEUTICAL CO. LTD., SYSTIMMUNE, INC.
Assigned to SYSTIMMUNE, INC. reassignment SYSTIMMUNE, INC. Request for Assignment Assignors: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., SYSTIMMUNE, INC.
Application granted granted Critical
Publication of AU2018295118B2 publication Critical patent/AU2018295118B2/en
Priority to AU2025204860A priority Critical patent/AU2025204860A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2018295118A 2017-06-25 2018-06-22 Multi-specific antibodies and methods of making and using thereof Active AU2018295118B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204860A AU2025204860A1 (en) 2017-06-25 2025-06-27 Multi-specific antibodies and methods of making and using thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762524557P 2017-06-25 2017-06-25
US62/524,557 2017-06-25
PCT/US2018/039156 WO2019005639A2 (en) 2017-06-25 2018-06-22 MULTISPECIFIC ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204860A Division AU2025204860A1 (en) 2017-06-25 2025-06-27 Multi-specific antibodies and methods of making and using thereof

Publications (2)

Publication Number Publication Date
AU2018295118A1 AU2018295118A1 (en) 2020-02-06
AU2018295118B2 true AU2018295118B2 (en) 2025-04-17

Family

ID=64742644

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018295118A Active AU2018295118B2 (en) 2017-06-25 2018-06-22 Multi-specific antibodies and methods of making and using thereof
AU2025204860A Pending AU2025204860A1 (en) 2017-06-25 2025-06-27 Multi-specific antibodies and methods of making and using thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204860A Pending AU2025204860A1 (en) 2017-06-25 2025-06-27 Multi-specific antibodies and methods of making and using thereof

Country Status (10)

Country Link
US (1) US11787863B2 (cg-RX-API-DMAC7.html)
EP (1) EP3645049A4 (cg-RX-API-DMAC7.html)
JP (1) JP7399852B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250024104A (cg-RX-API-DMAC7.html)
CN (4) CN116199785A (cg-RX-API-DMAC7.html)
AU (2) AU2018295118B2 (cg-RX-API-DMAC7.html)
CA (1) CA3068045A1 (cg-RX-API-DMAC7.html)
IL (2) IL313468A (cg-RX-API-DMAC7.html)
SG (1) SG11201912864SA (cg-RX-API-DMAC7.html)
WO (1) WO2019005639A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260008861A9 (en) * 2017-06-25 2026-01-08 Systimmune, Inc. Anti-4-1bb antibodies and methods of making and using thereof
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
JP7383605B2 (ja) * 2017-06-25 2023-11-20 システィミューン, インク. 抗pd-l1抗体とその作製及び使用方法
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
CN118580364A (zh) * 2019-11-06 2024-09-03 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
EP3988568A1 (en) * 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
CN118974091A (zh) * 2022-04-11 2024-11-15 阿斯利康(瑞典)有限公司 T细胞结合蛋白
CA3262028A1 (en) * 2022-07-15 2025-06-13 Abl Bio Inc. Anti-ROR1 antibodies, bispecific antibodies containing it, and their uses
CN120813602A (zh) * 2022-12-20 2025-10-17 英克特诺治疗公司 用于治疗癌症的组合疗法
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
CN116143934B (zh) * 2023-03-21 2023-07-25 诺赛联合(北京)生物医学科技有限公司 一种干细胞外泌体提取试剂盒及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010136172A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
WO2015013671A1 (en) * 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
WO2015150447A1 (en) * 2014-04-02 2015-10-08 F. Hoffmann-La Roche Ag Multispecific antibodies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
CA2832136C (en) * 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
WO2007002223A2 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
CN103906533A (zh) * 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
PL3489261T3 (pl) * 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
HK1218549A1 (zh) 2013-06-26 2017-02-24 Numab Therapeutics AG 新型抗体框架
WO2015058861A1 (en) 2013-10-25 2015-04-30 Numab Ag Bispecific constructs and their use in the treatment of various diseases
CA3265373A1 (en) * 2014-02-20 2025-10-30 H. Lundbeck A/S Anti-acth antibodies and use thereof
US10428155B2 (en) * 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
EP3253790A4 (en) * 2015-02-06 2018-07-25 University of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
CN104829733B (zh) * 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
JP6932700B2 (ja) * 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
SG11201912865VA (en) 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010136172A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
WO2015013671A1 (en) * 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
WO2015150447A1 (en) * 2014-04-02 2015-10-08 F. Hoffmann-La Roche Ag Multispecific antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TIMOTHY J. EGAN ET AL: MABS, vol. 9, no. 1, 27 October 2016 (2016-10-27), US, pages 68 - 84, XP055467772, ISSN: 1942-0862, DOI: 10.1080/19420862.2016.1248012 *

Also Published As

Publication number Publication date
AU2018295118A1 (en) 2020-02-06
IL271257B2 (en) 2024-11-01
US20220002406A1 (en) 2022-01-06
KR20200092301A (ko) 2020-08-03
CN116948035A (zh) 2023-10-27
IL313468A (en) 2024-08-01
CN116041530A (zh) 2023-05-02
EP3645049A2 (en) 2020-05-06
EP3645049A4 (en) 2021-06-30
KR20250024104A (ko) 2025-02-18
RU2020102662A (ru) 2021-07-27
WO2019005639A2 (en) 2019-01-03
KR102763369B1 (ko) 2025-02-05
WO2019005639A3 (en) 2019-02-07
JP2020530777A (ja) 2020-10-29
SG11201912864SA (en) 2020-01-30
US11787863B2 (en) 2023-10-17
IL271257B1 (en) 2024-07-01
JP7399852B2 (ja) 2023-12-18
CN110831973A (zh) 2020-02-21
CN110831973B (zh) 2023-08-15
NZ760913A (en) 2024-10-25
AU2025204860A1 (en) 2025-07-17
CA3068045A1 (en) 2019-01-03
CN116199785A (zh) 2023-06-02
IL271257A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
KR102763369B1 (ko) 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
CN110891650B (zh) 制导和导航控制蛋白及其制造和使用方法
AU2018295119B2 (en) Multi-specific antibodies and methods of making and using thereof
KR102837521B1 (ko) Bcma에 결합하는 항체 및 이의 용도
AU2018250301B2 (en) Anti-ICOS agonist antibodies and uses thereof
CN106459203B (zh) 抗糖皮质激素诱导肿瘤坏死因子受体(gitr)的抗体及其用途
CN107922496B (zh) IL2Rβ/通用γ链抗体
KR20220033522A (ko) 항-cd73 항체와의 조합 요법
KR20180082563A (ko) 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
KR20170091179A (ko) Fap 및 dr5에 특이적인 이중특이성 항체, dr5에 특이적인 항체 및 사용 방법
KR102558418B1 (ko) Pd-1에 결합하는 항체 및 그 용도
CN110869392A (zh) 用抗gitr激动性抗体治疗癌症
KR20160072268A (ko) 항-efna4 항체-약물 접합체
WO2020214957A1 (en) Anti-pd-1 antibodies and uses thereof
TW202313110A (zh) 癌症之治療
CN115667297B (zh) 结合il6r的抗体及其用途
RU2837770C2 (ru) Мультиспецифические антитела и способы их получения и применения
RU2811477C2 (ru) Мультиспецифические антитела и способы их получения и применения
RU2773758C2 (ru) Связывающиеся с pd-1 антитела и способы их применения
RU2812280C1 (ru) Связывающиеся с pd-1 антитела и способы их применения
HK40018991B (en) Multi-specific antibodies and methods of making and using thereof
RU2839071C1 (ru) Антитела, связывающие siglec15, и варианты их применения
CN113368232B (zh) 多特异性抗原结合蛋白及其应用
HK40019010B (en) Multi-specific antibodies and methods of making and using thereof
CN117460529A (zh) 抗icos抗体的用途

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SYSTIMMUNE, INC.

Free format text: FORMER APPLICANT(S): SICHUAN BAILI PHARMACEUTICAL CO. LTD.; SYSTIMMUNE, INC.

Owner name: BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.

Free format text: FORMER APPLICANT(S): SICHUAN BAILI PHARMACEUTICAL CO. LTD.; SYSTIMMUNE, INC.

PC1 Assignment before grant (sect. 113)

Owner name: SYSTIMMUNE, INC.

Free format text: FORMER APPLICANT(S): BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.; SYSTIMMUNE, INC.

FGA Letters patent sealed or granted (standard patent)